Context Therapeutics (CNTX) stock forecast for 2022
Last update: January 27, 2023 (06:55)Sector: Healthcare
The share price of Context Therapeutics Inc. (CNTX) now
50/200 Day Moving Average: $0.939 / $1.5
This figure corresponds to the Average Price over the previous 50/200 days. For Context Therapeutics stocks, the 50-day moving average is the resistance level today.
For Context Therapeutics stocks, the 200-day moving average is the resistance level today.
Are you interested in Context Therapeutics stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Context Therapeutics stock price in 2022. How much will one Context Therapeutics share be worth in 2022? Is it worth taking profit / loss on Context Therapeutics stock now or waiting? What are analysts' forecasts for Context Therapeutics stock?
We forecast Context Therapeutics stock performance using neural networks based on historical data on Context Therapeutics stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account. The Context Therapeutics stock prediction results are shown below and presented as a graph, table and text information.
Context Therapeutics stock forecasts are adjusted once a day based on the closing price of the previous trading day.
The minimum target price for Context Therapeutics analysts is $None.
Today 200 Day Moving Average is the resistance level (1.5 $).
50 Day Moving Average is the resistance level (0.939 $).
Historical and forecast chart of Context Therapeutics stock
The chart below shows the historical price of Context Therapeutics stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Context Therapeutics stock price can be found in the table below.
Context Therapeutics (CNTX) Forecast for 2022
Context Therapeutics information and performance
Context Therapeutics is a clinical-stage American biotechnology company that develops drugs for the treatment of cancer in women. In particular, the therapeutic focus of the company’s candidate drugs is directed towards breast cancer as well as gynecological oncology. In the clinical stage, Context Therapeutics has two directions: it is a drug for the prevention and treatment of ovarian, endometrial and breast cancer ONA-XR and the Claudin 6 program, which is a stage for the study of a bispecific monoclonal antibody against CD3 x anti-Claudin 6 (CLDN6) antigen ( bsAbs).
3675 MARKET STREET, SUITE 200, PHILADELPHIA, PA, US
Market capitalization is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of shares in the company outstanding by the market price of one share.
EBITDA is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
Context Therapeutics price target for 2022 by month
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.